Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Latuda in Schizophrenia
NCT01614912Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma. Started Aug 2012; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01614912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01614912.